Research Topics
| Sherri Machele DonatSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selectionJeffrey M Holzbeierlein
Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 E. 68th Street, New York, NY 10021, USA
J Urol 172:878-81. 2004..CONCLUSIONS: In highly selected patients with invasive bladder cancer, partial cystectomy offers acceptable outcomes. Concomitant CIS and presence of metastases to regional lymph nodes predict advanced recurrence...- Peri-operative care in patients treated for testicular cancerS M Donat
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Semin Surg Oncol 17:282-8. 1999..Pre-operative evaluation and judicious fluid management have been shown to reduce the risk of life-threatening respiratory complications in the postoperative period... - Impact of body mass index on survival of patients with surgically treated renal cell carcinomaS Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 175:46-52. 2006..We evaluated the impact of BMI and other clinical/pathological characteristics on survival in patients with RCC treated with radical or partial nephrectomy... 
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experienceS Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
Eur Urol 55:177-85. 2009..However, in a recent report from the National Cancer Database (NCDB), only 11.6% of stage III BCa patients received perioperative chemotherapy, the majority in the adjuvant setting...- Evaluation and follow-up strategies for superficial bladder cancerS Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Urol Clin North Am 30:765-76. 2003..The advent and long-term success of orthotopic continent diversions has made the decision for early radical cystectomy more palatable to both the patient and physician... - Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancerS Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Urol 170:1777-80. 2003..High fluid intake has been associated with a decreased risk of bladder cancer development in men. We evaluated whether higher fluid intake can impact tumor recurrence rates in patients with superficial bladder cancer... - Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?S Machele Donat
Department of Urology, the Genitourinary Oncology Service in the Department of Medicine MIM, and the Department of Epidemiology and Biostatistics AC, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 183:2171-7. 2010..4% of those with similar stage disease age 65 to 79 years, reflecting concern for perioperative morbidity. We evaluated the morbidity and survival outcomes of octogenarians treated with radical cystectomy at a tertiary cancer center... - Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus realityS Machele Donat
Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Natl Compr Canc Netw 7:40-7. 2009.... - Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?S Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
World J Urol 24:557-64. 2006 - Standards for surgical complication reporting in urologic oncology: time for a changeSherri Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York 10021, USA
Urology 69:221-5. 2007..This study analyzes the quality of complication reporting in the urologic literature... 
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experienceAtreya Dash
Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 113:2471-7. 2008..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...- Clinical outcomes of primary bladder carcinoma in situ in a contemporary seriesDaher C Chade
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 184:74-80. 2010..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy... - Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancerDavid S Yee
Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 183:1751-6. 2010..We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities... - Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tractMatthew D Galsky
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 69:255-9. 2007..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management... - Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancerHarry W Herr
Departments of Urology (Genitourinary Oncology Service, Medicine and Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
J Urol 167:1295-8. 2002..Such information is important not only for the therapy and prognosis of individuals, but also for identifying those who may benefit from adjuvant chemotherapy... - Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancerGanesh V Raj
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 107:2167-72. 2006..However, the overall risk of recurrence is low and is not clearly associated with overall survival. The data do not support routine intraoperative frozen sections to assess ureteral involvement... - Defining optimal therapy for muscle invasive bladder cancerHarry W Herr
Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA
J Urol 177:437-43. 2007..We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy... - A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrencesHarry W Herr
Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
BJU Int 102:1111-4. 2008.... - Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancerTheresa M Koppie
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer 112:2384-92. 2008..Also evaluated was whether ACCI was associated with clinicopathologic and treatment characteristics... - Natural history of positive urinary cytology after radical cystectomyGanesh V Raj
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 176:2000-5; discussion 2005. 2006..Additionally, these data indicate the need for diligent evaluation for recurrent disease and potentially the role of early adjuvant therapy in patients with positive cytology after radical cystectomy... - Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?Harry W Herr
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 177:75-9; discussion 79. 2007..We determined whether pathological findings on restaging transurethral resection predict early stage progression of T1 bladder cancer... - Complications after radical and partial nephrectomy as a function of ageWilliam T Lowrance
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 183:1725-30. 2010..We determined if the association of age and perioperative outcomes differed between nephrectomy types... - Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancerPadmanee Sharma
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Immun 3:19. 2003..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35... - Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cmS Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 171:636-9. 2004..We report our experience with office fulguration of small, recurrent, low grade papillary tumors using flexible cystodiathermy... - Bladder cancer as a prognostic factor for upper tract transitional cell carcinomaMichael Mullerad
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 172:2177-81. 2004..CONCLUSIONS: This study demonstrates that a history of BTCC (invasive or superficial) has an adverse effect on the prognosis of patients diagnosed with UTTCC independent of primary tumor stage... - Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancerGuido Dalbagni
Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Eur Urol 56:903-10. 2009..To evaluate the indications for early and deferred cystectomy and to report the impact of this tailored approach on survival... - A re-staging transurethral resection predicts early progression of superficial bladder cancerHarry W Herr
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 97:1194-8. 2006..To determine whether pathology on a re-staging transurethral resection (TUR) predicts the early progression of superficial bladder cancer... - Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancerJaspreet S Sandhu
Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
BJU Int 98:59-62. 2006.... - Placement of transileal conduit retrograde nephroureteral stents in patients with ureteral obstruction after cystectomy: technique and outcomeWilliam Alago
Division of Interventional Radiology and Image Guided Therapy, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Ste H118, New York, NY 10021, USA
AJR Am J Roentgenol 191:1536-9. 2008..The objective of our article is to describe the technique, complications, and long-term results of transileal conduit retrograde nephroureteral stents placed for ureteral obstruction after radical cystectomy... - Management of low grade papillary bladder tumorsHarry W Herr
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 178:1201-5; discussion 1205. 2007..We evaluated the management and treatment outcomes of low grade papillary bladder tumors... - Correlation of cystoscopy with histology of recurrent papillary tumors of the bladderHarry W Herr
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Urol 168:978-80. 2002..CONCLUSIONS: Urologists can usually identify noninvasive, low grade recurrent papillary tumors on followup cystoscopy that may be treated safely with outpatient fulguration... - Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrenceOfer Yossepowitch
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Urol 169:177-81. 2003.... - Clinical outcome of primary versus secondary bladder carcinoma in situDaher C Chade
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 184:464-9. 2010..Differences in clinical outcome are still unclear between primary and secondary bladder carcinoma in situ. We compared the clinical outcomes of primary and secondary carcinoma in situ, and identified predictive factors... - Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomyJoseph A Pettus
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Eur Urol 53:370-5. 2008.... - Early nasogastric tube removal combined with metoclopramide after postchemotherapy retroperitoneal lymph node dissection for metastatic testicular nonseminomatous germ cell tumorJohn W Davis
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Urology 59:579-83. 2002..The role that promotility agents play as a necessary component of safe, early NGT removal is unclear... - Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II studyBadrinath R Konety
Department of Urology, Memorial Sloan-Kettering Cancer Center and Cornell University, New York, New York 10021, USA
J Urol 171:709-13. 2004..Positive surgical margin rates are low. This approach yielded good local control of disease, however impact on tumor recurrence and survival is not known... - Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patientsOfer Yossepowitch
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 176:482-5. 2006..Further studies are warranted to assess the safety and efficacy of bacillus Calmette-Guerin instillations in critically immunocompromised patients... - Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer?Jason Hafron
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 173:1513-7. 2005..Obesity is estimated to account for up to 20% of all cancer deaths. We evaluated the effect of body mass index (BMI) on survival in patients undergoing radical or partial cystectomy for bladder cancer... - Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologiesWilliam T Lowrance
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BJU Int 105:16-20. 2010.... - Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillanceWilliam Tran
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 179:96-100. 2008..However, these recurrence rates are based on statistical methodology that does not take censoring into account. We used landmark time analysis to determine whether the risk of upper tract recurrence changes over time... - Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancerGanesh V Raj
Department of Urology, 353 E 68th St, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:3095-100. 2006..Methodology for determining CrCl and/or renal eligibility for cisplatin-based chemotherapy in patients with bladder cancer should be re-examined... - Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tractGanesh V Raj
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 175:2038-41; discussion 2041. 2006..However, the concordance with histological subclassification on prior cytology results ranges from 19% for adenocarcinoma to 60% for squamous cell carcinoma... - Perioperative clinical thromboembolic events after radical or partial nephrectomyJoseph A Pettus
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 68:988-92. 2006..Thromboembolic events are rare but are more likely to occur in patients with coronary artery disease, cardiac arrhythmia, prior DVT, Stage 3 or 4 tumors, or a large estimated blood loss... - Urinary diversion: options, patient selection, and outcomesDipen J Parekh
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 34:98-109. 2007.... - Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodologyTimothy Siegrist
Department of Urology, Memorial Sloan Kettering Cancer, New York, NY 10021, USA
Urol Oncol 28:112-7. 2010..Variability in reporting methodologies may affect findings; therefore, we utilized a standardized reporting methodology to evaluate for gender differences in perioperative complications at a tertiary cancer center... - Use of urinary biomarkers for bladder cancer surveillance: patient perspectivesOfer Yossepowitch
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 177:1277-82; discussion 1282. 2007..We assessed whether patients would accept a urine biomarker assay over flexible cystoscopy for monitoring bladder cancer...